The Dalbavancin Market may benefit from continued research into its use across selected infection types and patient populations. Clinical evidence can help clarify where long-acting treatment approaches may be suitable, while approved indications and established guidance remain central to prescribing decisions. The Dalbavancin Market size is expected to reach US$ 1,216.61 million by 2034 from...